Detalhe da pesquisa
1.
Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence.
Cell
; 179(1): 236-250.e18, 2019 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31495571
2.
Identification of bacteria-derived HLA-bound peptides in melanoma.
Nature
; 592(7852): 138-143, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33731925
3.
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Lancet Oncol
; 24(1): 33-44, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460017
4.
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
N Engl J Med
; 383(12): 1139-1148, 2020 09 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32877599
5.
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
N Engl J Med
; 381(7): 626-636, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166680
6.
The moderating and mediating roles of mindfulness and rumination on COVID-19 stress and depression: A longitudinal study of young adults.
J Couns Psychol
; 69(5): 732-744, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35737540
7.
microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy.
Cancer Immunol Immunother
; 70(6): 1541-1555, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33201337
8.
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
N Engl J Med
; 377(19): 1813-1823, 2017 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28891408
9.
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response.
Mol Carcinog
; 59(7): 736-744, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32250515
10.
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(5): 701-710, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30928620
11.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Lancet Oncol
; 20(9): 1239-1251, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31345627
12.
Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Oncologist
; 24(5): 640-647, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30777894
13.
TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma.
Cancer Immunol Immunother
; 68(9): 1493-1500, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31501955
14.
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
Br J Cancer
; 119(6): 670-674, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30202085
15.
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Lancet
; 390(10105): 1853-1862, 2017 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28822576
16.
Improved overall survival in melanoma with combined dabrafenib and trametinib.
N Engl J Med
; 372(1): 30-9, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25399551
17.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
N Engl J Med
; 372(26): 2521-32, 2015 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25891173
18.
Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients.
Cancer Immunol Immunother
; 67(8): 1221-1230, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29845338
19.
Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
Am J Hematol
; 93(12): 1485-1492, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30187944
20.
Adoptive T cell therapy: An overview of obstacles and opportunities.
Cancer
; 123(S11): 2154-2162, 2017 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28543698